Our results thereby add another facet of JunB to the pathophysiologic functions in MM and underscore worldwide efforts to directly target specific pathognomic AP-1 TFs such as JunB as one of the most promising future strategies in cancer and in MM therapy in particular. This evidence concerns the gene JUNB and cancer.